Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1498403 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.75Day −2.14%1Y −33.4%Off 52W high −39.7%Vol (1Y) 61.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,770 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover5.7d |
| 13F net flow (QoQ)−0.00% |
| Top-10 13F concentration100.0% |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.2M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−0.7% |
| 1Y−33.4% |
| 3Y−95.5% |
| 5Y−97.9% |
| 10Y−99.4% |
| Since incept. (ann.)−37.3% |
Total return through 2026-07-29 · series begins 2011-07-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)61.8% |
| Ann. volatility (3Y)91.1% |
| Sharpe (1Y)−0.37 |
| Sharpe (3Y)−0.65 |
| Max drawdown (1Y)−50.9% |
| Max drawdown (3Y)−97.8% |
| Beta (3Y vs SPY)1.90 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| XTX Topco Ltd | 10,941 | $25,274 | 0.00% | new |
| RHUMBLINE ADVISERS | 2,353 | $5,432 | 0.00% | −29.8% |
| BNP PARIBAS FINANCIAL MARKETS | 1,800 | $4,140 | 0.00% | +20.0% |
| WELLS FARGO & COMPANY/MN | 1,750 | $4,025 | 0.00% | +0.0% |
| CITIGROUP INC | 1,728 | $3,992 | 0.00% | −15.2% |
| UBS Group AG | 529 | $1,217 | 0.00% | −72.9% |
| Nemes Rush Group LLC | 250 | $575 | 0.00% | +0.0% |
| MORGAN STANLEY | 100 | $230 | 0.00% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
No reported quarters on file for BLRX.
